Anavex Life Sciences Corp (AVXL)

[sokol]

Yes, thank you both, Bio and Nidan, for your efforts and insight. You have provided a big leap in knowledge and understanding of the difficulties that must be overcome to make the leap to finding an effective treatment for AD that regulatory authorities will approve.

As I believe you point out, it may be that adequate or acceptable measures may be more evident with Parkinson's and some other CNS diseases. If so, our PDD trial may help to demonstrate this relatively soon. The PDD trial is shorter, and it includes fewer trial participants.

We should also look more closely how, if ever, AVXL 2-73 may be approved in Australia and what that may mean.

You have provided much food for thought. I, for one, will undoubtedly be thinking about this.